Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kindai University · University of California, Los Angeles · +21 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
609
total citations
- FWCI
- 59.59
- Percentile
- 100%
- References
- 38
Citations per year
Authors
131- KNKazuhiko NakagawaCorresponding
Kindai University
- EBEdward B. Garon
University of California, Los Angeles
- TSTakashi Seto
National Hospital Organization Kyushu Cancer Center
- MNMakoto Nishio
The Cancer Institute Hospital, Japanese Foundation For Cancer Research
- SPSantiago Ponce Aix
Hospital Universitario 12 De Octubre
Topics & keywords
Topics
Keywords
- Erlotinib
- Ramucirumab
- Medicine
- Internal medicine
- Oncology
- Afatinib
- Clinical endpoint
- Population
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.